Literature DB >> 32181121

Structural modification of aspirin to design a new potential cyclooxygenase (COX-2) inhibitors.

Monir Uzzaman1, Tareq Mahmud1.   

Abstract

Aspirin (Asp) is one of the most important and ancient member of nonsteroidal anti-inflammatory drugs (NSAID), commonly used in medication of fever, pain and inflammation. It can inhibit the synthesis of prostaglandin by blocking the cyclooxygenase (COX). Attempts have been taken to analyze aspirin together with some of its modified derivatives applying quantum mechanical calculations in order to compare their physicochemical and biochemical properties. Density functional theory (DFT) with B3LYP/6-31G (d, p) basis set has been employed to elucidate their thermal, molecular orbital, equilibrium geometrical properties in gas phase. Molecular docking and nonbonding interactions have been performed against human cyclooxygenase-2 protein 5F1A to investigate the binding affinity and mode(s) of newly designed aspirin derivatives. ADMET prediction has been utilized to compare the absorption, metabolism, and carcinogenic properties of new derivatives with parent drug (Asp). Thermal and geometrical results support the thermochemical stability and equilibrium geometry of all the structures. From the molecular docking simulation, most of the derivatives exhibited better binding affinity than parent drug (Asp) with the receptor protein (5F1A). ADMET prediction disclosed the improved pharmacokinetic properties with lower acute oral toxicity of some derivatives. Based on quantum chemical, molecular docking and ADMET analysis, this investigation can be useful to understand the physicochemical and biochemical/biological activities of Asp and its modified derivatives to search a new antipyretic analgesic drug. © Springer-Verlag GmbH Germany, part of Springer Nature 2020.

Entities:  

Keywords:  ADMET; Aspirin; Cyclooxygenase; HOMO–LUMO; Molecular docking

Year:  2020        PMID: 32181121      PMCID: PMC7056757          DOI: 10.1007/s40203-020-0053-0

Source DB:  PubMed          Journal:  In Silico Pharmacol        ISSN: 2193-9616


  45 in total

1.  Aspirin. An ab initio quantum-mechanical study of conformational preferences and of neighboring group interactions.

Authors:  R Glaser
Journal:  J Org Chem       Date:  2001-02-09       Impact factor: 4.354

2.  Universal solvation model based on solute electron density and on a continuum model of the solvent defined by the bulk dielectric constant and atomic surface tensions.

Authors:  Aleksandr V Marenich; Christopher J Cramer; Donald G Truhlar
Journal:  J Phys Chem B       Date:  2009-05-07       Impact factor: 2.991

3.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.

Authors:  F Catella-Lawson; M P Reilly; S C Kapoor; A J Cucchiara; S DeMarco; B Tournier; S N Vyas; G A FitzGerald
Journal:  N Engl J Med       Date:  2001-12-20       Impact factor: 91.245

4.  Small-molecule library screening by docking with PyRx.

Authors:  Sargis Dallakyan; Arthur J Olson
Journal:  Methods Mol Biol       Date:  2015

Review 5.  Halogen bonding for rational drug design and new drug discovery.

Authors:  Yunxiang Lu; Yingtao Liu; Zhijian Xu; Haiying Li; Honglai Liu; Weiliang Zhu
Journal:  Expert Opin Drug Discov       Date:  2012-03-30       Impact factor: 6.098

Review 6.  COX-1 and COX-2 tissue expression: implications and predictions.

Authors:  L J Crofford
Journal:  J Rheumatol Suppl       Date:  1997-07

7.  Optimization of structures, biochemical properties of ketorolac and its degradation products based on computational studies.

Authors:  Monir Uzzaman; Mohammad Nasir Uddin
Journal:  Daru       Date:  2019-02-19       Impact factor: 3.117

8.  A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Authors:  Paul M Ridker; Nancy R Cook; I-Min Lee; David Gordon; J Michael Gaziano; Joann E Manson; Charles H Hennekens; Julie E Buring
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

Review 9.  Aspirin and Cancer.

Authors:  Paola Patrignani; Carlo Patrono
Journal:  J Am Coll Cardiol       Date:  2016-08-30       Impact factor: 24.094

Review 10.  P-glycoprotein Inhibition for Optimal Drug Delivery.

Authors:  Md Lutful Amin
Journal:  Drug Target Insights       Date:  2013-08-19
View more
  3 in total

1.  Computational Evaluation of Bioactive Compounds from Colocasia affinis Schott as a Novel EGFR Inhibitor for Cancer Treatment.

Authors:  Toheeb A Balogun; Nureni Ipinloju; Olayemi T Abdullateef; Segun I Moses; Damilola A Omoboyowa; Akinwumi C James; Oluwatosin A Saibu; Wumi F Akinyemi; Ebenezer A Oni
Journal:  Cancer Inform       Date:  2021-10-08

2.  Mollusc-Derived Brominated Indoles for the Selective Inhibition of Cyclooxygenase: A Computational Expedition.

Authors:  Md Mominur Rahman; Md Junaid; S M Zahid Hosen; Mohammad Mostafa; Lei Liu; Kirsten Benkendorff
Journal:  Molecules       Date:  2021-10-29       Impact factor: 4.411

3.  Characterization, molecular modeling and pharmacology of some 2́-hydroxychalcone derivatives as SARS-CoV-2 inhibitor.

Authors:  Mohammad Nasir Uddin; Sayeda Samina Ahmed; Monir Uzzaman; Md Nazmul Hassan Knock; Wahhida Shumi; Abul Fazal Md Sanaullah; Md Mosharef Hossain Bhuyain
Journal:  Results Chem       Date:  2022-03-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.